Thalidomide: Chemistry, therapeutic potential and oxidative stress induced teratogenicity

Current Topics in Medicinal Chemistry

Volumn 12, Issue 13, 2012, Pages 1436-1455

  Kumar, Neeraj ^a   Sharma, Upendra ^a   Singh, Chitra ^a   Singh, Bikram ^a  

^a CSIR INSTITUTE OF HIMALAYAN BIORESOURCE TECHNOLOGY   (India)

Author keywords

Biological activities; Metabolism; Oxidative stress; Synthesis; Thalidomide

Indexed keywords

CLARITHROMYCIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; LENALIDOMIDE; STEROID; THALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIANGIOGENIC ACTIVITY; APHTHOUS STOMATITIS; BEHCET DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; DISCOID LUPUS ERYTHEMATOSUS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; EMBRYOTOXICITY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LICHEN PLANUS; MAINTENANCE DRUG DOSE; MICROWAVE IRRADIATION; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEURODERMATITIS; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; REVIEW; SARCOIDOSIS; SEDATION; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; HUMANS; MULTIPLE MYELOMA; OXIDATIVE STRESS; TERATOGENS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864540510     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612801784407     Document Type: Review

References (208)

1. Mellin, G.W.; Katzenstein, M. The saga of thalidomide: neuropathy to embryopathy, with case reports of congenital anomalies. N. Engl. J. Med., 1962, 267, 1184-1192.
2. Mellin, G.W.; Katzenstein, M. The saga of thalidomide: neuropathy to embryopathy, with case reports of congenital anomalies. N. Engl. J. Med., 1962, 267, 1238-1244.
3. Franks, M.E.; Macpherson, G.R.; Figg, W.D. Thalidomide. Lancet., 2004, 363, 1802-1811.
4. Teo, S.; Resztak, K.; Scheffler, M. Thalidomide in the treatment of leprosy. Microbes Infect., 2002, 4, 1193-1202.
5. Kim, J.H.; Scialli, A.R. Thalidomide: The tragedy of birth defects and the effective treatment of disease, Toxicological Sciences, 2011, 122(1), 1-6.
6. Stephens, T.; Brynner, R. Dark Remedy: The impact of thalidomide and its revival as a vital medicine. Cambridge, MA: Perseus Publishing, 2001.
7. Corral, L.; Muller, G.; Moreira, A. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol. Med., 1996, 2, 506-515.
8. Moreira, A.; Sampaio, E.; Zmuidzinas, A.; Frindt, P. Smith, K.; Kaplan, G. Thalidomide exerts its inhibitory action on TNF-alpha by enhancing mRNA degradation. J. Exp. Med., 1993, 177, 1675-1680.
9. Noman, A. S. M.; Koide, N.; Khuda, I. I. E.; Dagvadori, J.;Tumurkhuu, G.; Naiki, Y.; Komatsu, T.; Yoshida, T. Yokochi, T. Thalidomide inhibits lipopolysaccharide-induced nitric oxide production and prevents lipopolysaccharide-mediated lethality in mice. FEMS Immunol Med Microbiol., 2009, 56, 204-211.
10. Corral, L.; Haslett, P.; Muller, G. Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol., 1999, 163, 380-386.
11. Tseng, S.; Pak, G.; Washenik, K. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol., 1996, 35(6), 969-979.
12. Niwayama, S.; Turk, B.E.; Liu, J.O. Potent inhibition of tumor necrosis factor-α production by tetrafluorothalidomide and tetrafluorophthalimides. J. Med. Chem., 1996, 39, 3044-3045.
13. Muller, G.W.; Corral, L.G.; Shire, M.G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D.I. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem., 1996, 39, 3238-3240.
14. Palumbo, A.; Dimopoulos, M.; Miguel, J.S.; Harousseau, J.; Attal M.; Hussein, M.; Knop, S.; Ludwig, H.; Lilienfeld-Toal, M.; Sonneveld, P. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myleoma. Blood Reviews., 2009, 23(2), 87-93.
15. Palumbo, A.; Miguel, J.S.; Sonneveld, P.; Moreau, P.; Drach, J.; Morgan, G.; Einsele, H. Lenalidomide: A new therapy for multiple myeloma. Cancer Treatment Reviews., 2008, 34(3), 283-291.
16. McBride W.G. Thalidomide and congenital abnormalities. Lancet., 1961, 2, 1358. Case report.
17. Lenz, W. Thalidomide and congenital abnormalities. Lancet., 1962, 1, 45. Case report.
18. Sheskin, J. The treatment of lepra reaction in lepromatous leprosy: fifteen years experience with thalidomide. Int. J. Dermatol., 1980, 19, 318-322.
19. Zeldis, J.; Williams, B.; Thomas, S.; Elsayed, M. STEPS™: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther., 1999, 21, 319-330.
20. Aweeka, E.; Trapnell, C.; Chernoff, M. Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG Protocol 251. J. Clin. Pharmacol., 2001, 41, 1091-1097.
21. Hamza, M. H. Treatment of Behçet's disease with thalidomide. Clin. Rheumatol., 1986, 5(3), 365-371.
22. Eleutherakis-Papaiakovou, V.; Bamias, A.; Dimopoulos, M.A. Thalidomide in cancer medicine. Annals. of Oncology., 2004, 15, 1151-1160.
23. Wohl, D.A.; Aweeka, F.T.; Schmitz, J. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J. Infect. Dis., 2002, 185, 359-1363.
24. Wintersk, W.; Frankus, E. Thalidomide enantiomers. Lancet., 1992, 339, 365.
25. Krenn, M.; Gamcsik, M.E.; Vogelsang, G.B. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-f~-cyclodextrin. J. Pharm. Sci., 1992, 81, 685-689.
26. Eriksson, T.; Bjorkman, S.; Roth, B. Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality, 1998, 10, 223-228.
27. Eriksson, T.; Bjorkman, S. Handling of blood samples for determination of thalidomide. Clin. Chem., 1997, 43, 1094-1096.
28. Eriksson, T.; Bjorkman, S.; Roth, B.; Hoglund, P. Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol., 2000, 52, 807-817.
29. Sampaio, E.P.; Sarno, E.N.; Gallily, R.; Cohn, Z.A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med., 1991, 173, 699-703.
30. Meyring, M.; Mühlbacher, J.; Messer, K.; Kastner-Pustet, N.; Bringmann, G.; Mannschreck, A.; Blaschke, G. In Vitro Biotransformation of (R)-and (S)-Thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites. Anal Chem., 2002, 74, 3726-3735.
31. De Camp, W.H. The FDA perspective on the development of stereoisomers. Chirality, 1989, 1(1), 2-6.
32. Chirality. The Lancet., 1990, 336, 1100-1101.
33. Lien, E.J. Chirality and drug targeting: pros and cons. J. Drug Target., 1995, 2, 527-532.
34. Wnendt, S.; Zwingenberger, K. Thalidomide's chirality. Nature, 1997, 385, 303-304.
35. Lu, J.; Palmer, B.D.; Kestell, P.; Browett, P.; Baguley, B.C. Muller, G.; Ching, L. Thalidomide metabolites in mice and patients with multiple myeloma. Clinical Cancer Research, 2003, 9, 1680-1688.
36. Lu, J.; Helsby, N.; Palmer, B.D.; Tingle, M.; Baguley, B.C.; Kestell, P.; Ching, L. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J. of Pharmacol. Experi. Therapeutics, 2004, 310, 571-577.
37. Bauer, K.S.; Dixon, S.C.; Figg, W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent. Biochem. Pharmacol., 1998, 55, 1827-1834.
38. Marriott, J.B.; Westby, M.; Dalgleish, A.G. Therapeutic potential of TNF-α inhibitors old and new. Drug Discovery Today, 1997, 2, 273-282.
39. Moreira, A.L.; Sampaio, E.P.; Zmuidzinas, A.; Frindt, P.; Smith, K.A.; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., 1993, 177, 1675-1680.
40. Sampaio, E.P.; Sarno, E.N.; Galilly, R.; Cohn, Z.A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 1991, 173, 699-703.
41. Marriott, J.B.; Clarke, I.A.; Dredge, K.; Muller, G.; Stirling, D.; Dalgleish, A.G. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol., 2002, 130, 75-84.
42. Jin, S.H.; Kim, T.I.; Yang, K.M.; Kim, W.H. Thalidomide destabilizes cyclooxygenase-2 m-RNA by inhibiting p38 mitogenactivated protein kinase and cytoplasmic shuttling of HuR. Eur. J. Pharmacol., 2007, 558, 14-20.
43. Ronkina, N.; Menon, M.B.; Schwermann, J.; Tiedje, C.; Hitti, E.; Kotlyarov, A.; Gaestel, M. MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem. Pharmacol., 2010, 80, 1915-1920.
44. Singhal, S.; Mehta, J. Thalidomide in cancer: potential uses and limitations. Bio. Drugs, 2001, 15, 163-172.
45. Rowland, T.L.; McHugh, S.M.; Deighton, J.; Dearman, R.J.; Ewan, P.W.; Kimber, I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology, 1998, 40, 11-20.
46. Meierhofer, C.; Dunzendorfer, S.; Wiedermann, C.J. Theoretical basis for the activity of thalidomide. Bio Drugs, 2001, 15, 681-703.
47. Hayashi, T.; Hideshima, T.; Anderson, K.C. Novel therapies for multiple myeloma. Br. J. Haematol., 2003, 120, 10-17.
48. Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Shtil, A.A.; Dalton, W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 1999, 93, 1658-67.
49. Hideshima, T.; Chauhan, D.; Shima, Y. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96, 2943-2950.
50. D'Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA., 1994, 91, 4082-4085.
51. Haslett, P.A.; Corral, L.G.; Albert, M.; Kaplan, G. Thalidomide co stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med., 1998, 187, 1885-1892.
52. Davies, F.E.; Raje, N.; Hideshima, T. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 2001, 98, 210-216.
53. Fujita, J.; Mestre, J.R.; Zeldis, J.B.; Subbaramaiah, K.; Dannenberg, A.J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer. Res., 2001, 7, 3349-3355.
54. Yamada, M.; Kawai, M.; Kawai, Y.; Mashima, Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye. Res., 1999, 19, 300-304.
55. Daniel, T.O.; Liu, H.; Morrow, J.D.; Crews, B.C.; Marnett, L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res., 1999, 59, 4574-4577.
56. Tseng, S.; Pak, G.; Washenik, K. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol., 1996, 35(6), 969-979.
57. Iyer, C.G.; Languillon, J.; Ramanujam, K. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ., 1971, 45(6), 719-32.
58. Stirling, D.I. Thalidomide and its impact in dermatology. Semin. in Cutan Med Surg., 1988, 17(4), 231-242.
59. Calabrese, L.; Fleischer, A.B. Thalidomide: current and potential clinical applications. Am. J. Med., 2000, 108(6), 487-495.
60. Grinspan, D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad. Dermatol., 1985, 12(1), 85-90.
61. Hutton, K.P.; Rodgers, R.S. Recurrent aphthous stomatitis. Dermatol., 1987, 5, 761-768.
62. Radomsky, C.L.; Levine, N. Thalidomide. Dermatol. Clinics., 2001, 19(1), 87-103.
63. Revuz, J.; Guillaume, J.C.; Janier, M. Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis. Arch. Dermatol., 1990, 126, 923-927.
64. Rustin, M.H.; Gilkes, J.J.; Robinson, T.W. Pyoderma gangrenosum associated with Behcet's disease: treatment with thalidomide. J. Am. Acad. Dermatol., 1990, 23(5), 941-944.
65. Munro, C.S.; Cox, N.H. Pyoderma gangrenosum associated with Behcet's syndrome-response to thalidomide. Clin. Exp. Dermatol., 1988, 13(6), 408-410.
66. Hamuryudan, V.; Mat, C.; Saip, S. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med., 1998, 128, 443-450.
67. Shek, L.P.; Lim, D.L. Thalidomide in Behçet's disease. Biomed. Pharmacother. 2002, 56, 31-35.
68. Hamza, M.H. Treatment of Behçet's disease with thalidomide Clin. Rheumatol., 1986, 5, 365-371.
69. Farrell, A.M.; Black, M.M.; Bracka, A.; Bunker, C.B. Pyoderma gangrenosum of the penis. Br. J. Dermatol., 1998, 138(2), 337-340.
70. Federman, G.L.; Federman, D.G.; Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo. Clin. Proc., 2000, 75(8), 842-844.
71. Warren, K.J.; Nopper, A.J.; Crosby, D.L. Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematous. J. Am. Acad. Dermatol., 1998, 39(2), 293-295.
72. Kyriakis, K.P.; Kontochristopoulos, G.J.; Panteleos, D.N. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int. J. Dermatol., 2000, 39(13), 218-222.
73. Atra, E.; Sato, E.I. Treatment of the cutaneous lesions of systemic lupus erythematous with thalidomide. Clin. Exp. Rheumatol., 1993, 11(5), 487-493.
74. Scolari, F.; Harms, M.; Gilardi, S. Thalidomide in the treatment of chronic lupus erythematous. Dermatologica., 1982, 165(4), 355-362.
75. Walchner, M.; Meurer, M.; Plewig, G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematous. Int. J. Dermatol., 2000, 39(5), 383-388.
76. Stevens, R.J.; Andujar, C.; Edwards, C.J. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematous: experience in sixteen consecutive patients. Br. J. Rheumatol., 1997, 36(3), 353-359.
77. Dereure, O.; Basset-Seguin, N.; Guilhou, J.J. Erosive lichen planus: dramatic response to thalidomide. Arch. Dermatol., 1996, 132(11), 1392-1393.
78. Perez Alfonzo, R.; Weiss, E.; Piquero Martin, J.; Rondon Lugo, A. Generalized lichen planus with erosive lesions of the penis, treated with Thalidomide. Report of a case and review of the literature. Med. Cutan. Ibero. Lat. Am., 1987, 15(4), 32132-32136.
79. Young, B.G.; Hee, J.Y.; Sook, J.S. Thalidomide therapy on a case of prurigo nodularis. Ann Dermatol., 1993. 5(2), 117-120.
80. Herranz, P.; Pizarro, A.; De Lucas, R. Treatment of AIDs associated prurigo nodularis with Thalidomide. Clin Exp Dermatol., 1998, 23(5), 233-235.
81. Winkelmann, R.K.; Connolly, S.M.; Doyle, J.A.; Padhilha-Goncalves, A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol., 1994, 64(5), 412-417.
82. Van den Broek, H. Treatment of prurigo nodularis with thalidomide. Arch. Dermatol., 1998, 116(5), 571-572.
83. Arora, M.; Wagner, J.E.; Davies, S.M. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol. Blood Marrow Transplant., 2001, 7, 265-273.
84. Chao, N.J.; Parker, P.M.; Niland, J.C. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol. Blood Marrow Transplant., 1996, 2, 86-92.
85. Koc, S.; Leisenring, W.; Flowers, M.E. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 2000, 96, 3995-3996.
86. Rovelli, A.; Arrigo, C.; Nesi, F. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant, 1998, 21(6), 577-581.
87. Van de Poel, M.H.; Pasman, P.C.; Schouten, H.C. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med., 2001, 59(2), 45-49.
88. Kulkarni, S.; Powles, R.; Sirohi, B. Thalidomide after allogenic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant, 2003, 32, 165-170.
89. Schlossberg, H.; Klumpp, T.; Sabol, P. Severe cutaneous ulceration following treatment with thalidomide for GVHD. Bone Marrow Transplant, 2001, 27(2), 229-230.
90. Parker, P.M.; Chao, N.J.; Nademanee, A. Thalidomide as salvage therapy for; chronic graft-versus-host disease. Blood, 1995, 86(9), 3604-3609.
91. Wolkenstein, P.; Latarjet, J.; Roujeau, J.C. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet., 1998, 352, 1586-1589.
92. Ghislain, P.D.; Roujeau, J.C. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J., 2002, 8(1), 5.
93. Kaplan, G.; Thomas, S.; Fierer, D.S. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res. Hum. Retroviruses, 2000, 16, 1345-1355.
94. Gunzler, V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf., 1992, 7, 116-134.
95. Jacobson, J.M.; Greenspan, J.S.; Spritzler, J. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J Med., 1997, 336, 1487-1493.
96. Ramirez-Amador, V.A.; Esquivel-Pedraza, L.; Ponce-de-Leon, S.; Reyes-Teran, G.; Gonzalez-Guevara, M.; Sierra-Madero, J.G. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin. Infect. Dis., 1999, 28, 892-894.
97. Revuz, J.; Guillaume, J.C.; Janier, M. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch. Dermatol., 1990, 126, 923-927.
98. Paterson, D.L.; Georghiou, P.R.; Allworth, A.M.; Kemp, R.J. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin. Infect. Dis., 1995, 20, 250-254.
99. Ravot, E.; Lisziewicz, J.; Lori, F. New uses for old drugs in HIV infection: the role of hydrozyurea, cyclosporin and thalidomide. Drugs, 1999, 58(6), 953-963.
100. Gagnon, B.; Bruera, E. A review of the drug treatment of cachexia associated with cancer. Drugs, 1998, 55(5), 675-688.
101. Kaplan, G.; Thomas, S.; Fierer, D.S. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses, 2000, 16(14), 1345-1355.
102. Wanke, C. Single-agent/combination therapy of human immunodeficiency virus-related wasting. Semin Oncol., 1998, 25(2 suppl 6), 98-103.
103. Peuckmann, V.; Fisch, M.; Bruera, E. Potential novel uses of thalidomide: focus on palliative care. Drugs, 2000, 60(2), 273-292.
104. Krown, S.E. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol., 2001, 13(5), 374-381.
105. Singhal, S.; Mehta, J.; Desikan, R. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 1999, 341, 1565-1571.
106. Barlogie, B.; Desikan, R.; Eddlemon, P. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 2001, 98, 492-494.
107. Barlogie, B.; Tricot, G.; Anaissie, E. Thalidomide in the management of multiple myeloma. Semin. Oncol., 2001, 28, 577-582.
108. Leleu, X.; Magro, L.; Fawaz, A.; Bauters, F.; Facon, T.; Yakoub-Agha, I. Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood, 2002, 100, 1519-1520.
109. Rajkumar, S.V.; Fonseca, R.; Dispenzieri, A. Thalidomide in the treatment of relapsed multiple myeloma. Mayo. Clin. Proc., 2000, 75, 897-901.
110. Juliusson, G.; Celsing, F.; Turesson, I.; Lenhoff, S.; Adriansson, M.; Malm, C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol., 2000, 109, 89-96.
111. Bertolini, F.; Mingrone, W.; Alietti, A. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol., 2001, 12, 987-990.
112. Rajkumar, S.V. Current status of thalidomide in the treatment of cancer. Oncology (Huntingt), 2001, 15, 867-874.
113. Hus, M.; Dmoszynska, A.; Soroka-Wojtaszko, M. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica., 2001, 86, 404-408.
114. Tosi, P.; Zamagni, E.; Cellini, C. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica., 2002, 87, 408-414.
115. Yakoub-Agha, I.; Moreau, P.; Leyvraz, S. Thalidomide in patients with advanced multiple myeloma. Hematol. J., 2000, 1, 186-189.
116. Yakoub-Agha, I.; Attal, M.; Dumontet, C. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol. J., 2002, 3, 185-192.
117. Kneller, A.; Raanani, P.; Hardan, I. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. Br. J. Haematol., 2000, 108, 391-393.
118. Mileshkin, L.R.; Biagi, J.J.; Mitchell, P. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood, 2003, 102, 69-77.
119. Blade, J.; Esteve, J.; Rosinol, L. Thalidomide in refractory and relapsing multiple myeloma. Semin. Oncol., 2001, 28, 588-592.
120. Neben, K.; Moehler, T.; Egerer, G. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 2001, 7, 2675-2681.
121. Alexanian, R.; Weber, D.; Giralt, S.; Delasalle, K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann. Oncol., 2002, 13, 1116-1119.
122. Dimopoulos, M.A.; Zervas, K.; Kouvatseas, G. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol., 2001, 12, 991-995.
123. Palumbo, A.; Giaccone, L.; Bertola, A. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica., 2001, 86, 399-403.
124. Anagnostopoulos, A.; Weber, D.; Rankin, K.; Delasalle, K.; Alexanian, R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol., 2003, 121, 768-777.
125. Moehler, T.M.; Neben, K.; Benner, A. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 2001, 98, 3846-3848.
126. Coleman, M.; Leonard, J.; Lyons, L. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma., 2002, 43, 1777-1782.
127. Ahmad, I.; Islam, T.; Chanan-Khan, A. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant, 2002, 29, 577-580.
128. Rajkumar, S.V. Thalidomide in the treatment of multiple myeloma. Expert. Rev. Anticancer Ther., 2001, 1, 20-28.
129. Rajkumar, S.V.; Gertz, M.A.; Lacy, M.Q. Thalidomide as initial therapy for early-stage myeloma. Leukemia, 2003, 17, 775-779.
130. Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol., 2003, 21, 16-19.
131. Richardson, P.G.; Schlossman, R.L.; Weller, E. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100, 3063-3067.
132. Dimopoulos, M.A.; Zomas, A.; Viniou, N.A. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J. Clin. Oncol., 2001. 19, 3596-3601.
133. Dimopoulos, M.A.; Tsatalas, C.; Zomas, A. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin. Oncol., 2003, 30, 265-269.
134. Coleman, M.; Leonard, J.; Lyons, L.; Szelenyi, H.; Niesvizky, R.; Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin. Oncol., 2003, 30, 270-274.
135. Barosi, G.; Grossi, A.; Comotti, B.; Musto, P.; Gamba, G.; Marchetti, M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol., 2001, 114, 78-83.
136. Canepa, L.; Ballerini, F.; Varaldo, R. Thalidomide in agnogenic and secondary myelofibrosis. Br. J. Haematol., 2001, 115, 313-315.
137. Elliott, M.A.; Mesa, R.A.; Li, C.Y. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br. J. Haematol., 2002, 117, 288-296.
138. Piccaluga, P.P.; Visani, G.; Pileri, S.A. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study. Leukemia, 2002, 16, 1609-1614.
139. Piccaluga, P.P.; Visani, G.; Finelli, C.; Grafone, T.; Baccarani, M.; Tura, S. Efficacy of thalidomide in the treatment of myelodysplastic syndromes. Haematologica, 2002, 87, ELT18.
140. Raza, A.; Meyer, P.; Dutt, D. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 2001, 98, 958-965.
141. Thomas, D.A.; Kantarjian, H.M. Current role of thalidomide in cancer treatment. Curr. Opin. Oncol., 2000, 12, 564-573.
142. Zorat, F.; Shetty, V.; Dutt, D. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol., 2001, 115, 881-894.
143. Badros, A.; Morris, C.; Zangari, M.; Barlogie, B.; Tricot, G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma., 2002, 43, 1267-1271.
144. Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M.J. Cancer statistics, 2003. CA Cancer J. Clin., 2003, 53, 5-26.
145. Figg, W.D.; Dahut, W.; Duray, P. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgenindependent prostate cancer. Clin. Cancer Res., 2001, 7, 1888-1893.
146. Kurdziel, K.; Bacharach, S.; Carrasquillo, J. 8:45-9:00 Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin. Positron Imaging, 2000, 3, 144.
147. Drake, M.J.; Robson, W.; Mehta, P.; Schofield, I.; Neal, D.E.; Leung, H.Y. An open-label phase II study of low-dose thalidomide in androgenindependent prostate cancer. Br. J. Cancer, 2003, 88, 822-827.
148. Figg, W.D.; Arlen, P.; Gulley, J. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. Oncol., 2001, 28 (suppl), 62-66.
149. Petrylak, D.P.; Macarthur, R.; O'Connor, J. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin. Oncol., 1999, 26 (suppl), 28-33.
150. Sinibaldi, V.J.; Carducci, M.A.; Moore-Cooper, S.; Laufer, M.; Zahurak, M.; Eisenberger, M.A. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer, 2002, 94, 1457-1465.
151. Savarese, D.M.; Halabi, S.; Hars, V. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormonerefractory prostate cancer: a final report of CALGB 9780. J. Clin. Oncol., 2001, 19, 2509-2516.
152. Grabstald, H.; Golbey, R. Clinical experiences with thalidomide in patients with cancer. Clin. Pharmacol. Ther., 1965, 40, 298-302.
153. Eisen, T.; Boshoff, C.; Mak, I. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer, 2000, 82, 812-817.
154. Motzer, R.J.; Berg, W.; Ginsberg, M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol., 2002, 20, 302-306.
155. Stebbing, J.; Benson, C.; Eisen, T. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer, 2001, 85, 953-958.
156. Escudier, B.; Lassau, N.; Couanet, D. Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol., 2002, 13, 1029-1035.
157. Daliani, D.D.; Papandreou, C.N.; Thall, P.F. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer, 2002, 95, 758-765.
158. Minor, D.R.; Monroe, D.; Damico, L.A.; Meng, G.; Suryadevara, U.; Elias, L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest. New Drugs, 2002, 20, 389-393.
159. Desai, A.A.; Vogelzang, N.J.; Rini, B.I.; Ansari, R.; Krauss, S.; Stadler, W.M. A high rate of venous thromboembolism in a multiinstitutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer, 2002, 95, 1629-1636.
160. Amato, R.J. Thalidomide therapy for renal cell carcinoma. Crit. Rev. Oncol. Hematol., 2003, 46 (suppl), 59-65.
161. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent highgradegliomas. J Clin Oncol., 2000, 18, 708-715.
162. Shibata, N.; Yamamoto, T.; Toru, T. Synthesis of thalidomide. In: Eguchi, S. Ed. Topics in Heterocyclic Chemistry: Bioactive Heterocycles II, 8 vol. New York Springer Press 2007, 73-97.
163. Chemie Grunenthal. GB Patent, 1957, 768-821.
164. Ose, S.; Umemoto, S. JP Patent, 1960, 35 005 071.
165. Ose, S.; Yoshimura, Y.; Saeki, T. JP Patent, 1960, 35 005 277.
166. Muller, G.W. Cyclic amides. US Patent, 1997, 5 698 579.
167. Muller, G.W. Imides. US Patent, 1997, 5 605 914.
168. Muller, G.W.; Konnecke, W.E.; Smith, A.M.; Khetani, V.D. A Concise Two-Step Synthesis of Thalidomide. Org. Process Res. Dev., 1999, 3, 139-140.
169. Reepmeyer, J.C.; Cox, D.C. FDA monograph: guidelines to thalidomide synthesis.
170. Chang, M.Y.; Chang, C.H.; Chen, S.T.; Chang, N.C. A Synthesis of Thalidomide. J Chin Chem Soc (Taipei), 2002, 49, 383-385.
171. Chang, M.Y.; Lin, J.Y.C.; Chen, S. T; Chang, N.C. 8-Diazabicyclo[5.4.0]undec-7-ene: A remarkable base in the debromination of 4-or 5-substituted N-benzyl α-bromo-α-p-toluenesulfonylglutarimide. J. Chin. Chem. Soc. (Taipei), 2002, 49, 1015-1024.
172. Chang, M.Y.; Chen, S.T.; Chang, N.C. A synthesis of racemic thalidomide. Syn Commun., 2003, 33, 1375-1382.
173. Gao, L.; Yuan, X.; Guo, H.; Liu, X. CN Patent, 2003, 1 405 166.
174. Yuan, X.H.; Guo, H. Q.; Qiu, X.P.; Kang, C.Q.; Liu, X.D.; Gao, L.X. Chem. J. Chinese U., 2005, 26, 1477-1479.
175. Greig, N.H.;, Holloway, H.; Brossi, A.; Zhu, X.; Giordano, T.; Yu, Q.S.; Figg, W.D. 2005. WO Patent, 2 005 028 436.
176. Zhang, H. CN Patent. 2005, 1 597 680.
177. Alpegiani, M.; Mazzoni, A.; Vergani, D.; Cabri, W. EP Patent, 2005, 1 602 654.
178. Varala, R.; Adapa, S.R. A practical and efficient synthesis of thalidomide via Na/liq. NH3 methodology. Org. Proc. Res. Dev., 2005, 9, 853-856.
179. Casini, G.; Ferappi, M. Preparation of one optical antipode of 2-Phthalimido-glutarimide. Farmaco. Ed. Sci., 1964, 19, 563.
180. Shealy, Y.F.; Opliger, C.E.; Montgomery, J.A. D-and Lthalidomide. Chem. Ind., 1965, 1030.
181. Shealy, Y.F.; Opliger, C.E.; Montgomery, J.A. Synthesis of D-and L-thalidomide and related Studies. J. Pharm. Sci., 1968, 57, 757-764.
182. Blaschke, G.; Kraft, H.P.; Fickentscher, K.; Kohler, F. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittelforschun, 1979, 29, 1640-1642.
183. Blaschke, G.; Kraft, H. P; Markgraf, H. Optical resolution of thalidomide and other glutarimide derivatives. Chem. Ber., 1980, 113, 2318-2322.
184. Francotte, E.; Wolf, R.M. Chromatographic resolution on methylbenzoylcellulose beads. Modulation of the chiral recognition by variation of the position of the methyl group on the aromatic ring, J Chromatogr., 1992, 595, 63.
185. Reepmeyer, J.C. Separation of R-and S-Thalidomide by Reversed-Phase HPLC With α-cyclodextrin in the Mobile Phase. Chirality, 1996, 8, 11-17.
186. Chankvetadz, B.; Schulte, G.; Blaschke, G. Selected applications of capillaries with dynamic or permanent anodal electroosmotic flow in chiral separations by capillary electrophoresis. J. Pharm. Biomed. Anal., 1997, 15, 1577-1584.
187. Meyring, M.; Chankvetadze, B.; Blaschke, G. Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography. J. Chromatogr. A, 2000, 876, 157-167.
188. Meyring, M.; Muhlenbrock, C.; Blaschke, G. Electrophoresis, 2000, 21, 3270-3279.
189. Zhang, Y.; Watts, W.; Nogle, L.; McConnell, O. Rapid method development for chiral separation in drug discovery using multicolumn parallel screening and circular dichroism signal pooling, J. Chromatogr. A., 2004, 1049, 75-84.
190. Murphy-Poulton, S.F.; Boyle, F.; Gu X.Q.; Mather, L.E. Thalidomide enantiomers: Determination in biological samples by HPLC and vancomycin-CSP. J. Chromatogr. B, 2006, 831, 48-56.
191. Robin, S.; Zhu, J.; Galons, H.; Pham-Huy, C.; Claude, J.R. Tomas, A.; Viossat, B. A convenient asymmetric synthesis of thalidomide. Tetrahedron Asym., 1995, 6, 1249-1252.
192. Flaih, N.; Pham-Huy, C.; Galons, H. An expeditious synthesis of cyclic imides, Tetrahedron Lett., 1999, 40, 3697-3698.
193. Suzuki, E.; Shibata, N. Three step synthesis of (R)-and (S)-thalidomides from ornithine. Enantiomer., 2001, 6, 275.
194. Iong, J.; Shibata, N.; Toru, T. JP Patent, 2005, 336, 157.
195. Seijas-Vazquez, J.A.; Vazquez Tato, M.P.; Gonzalez-Bande, C.; Pacios-Lopez, B. ES Patent, 2003, 2 190 707.
196. Seijas, J.A.; Vazquez-Tato, M.P.; Gonzalez-Bande, C.; Martinez, M.M.; Pacios-Lopez, B. Microwave promoted synthesis of a rehabilitated drug: Thalidomide. Synthesis, 2001, 999-1000.
197. Hijji, Y.M.; Benjamin, E. 5th International electronic conference on synthetic organic chemistry. 1-30 September 2001, p 1084.
198. Hijji, Y.M.; Benjamin, E. 6th International electronic conference on synthetic organic chemistry. 1-30 September 2002, p 1084.
199. Hijji, Y.M.; Benjamin, E. 7th International electronic conference on synthetic organic chemistry. 1-30 November 2003, p 1084.
200. Hijji, Y.M.; Benjamin, E. 8th International electronic conference on synthetic organic chemistry. 1-30 November 2004, p 1084.
201. Xiao, Z.; Schaefer, K.; Firestine, S.; Li, P.K. Solid-phase synthesis of thalidomide and its analogues J. Comb. Chem., 2002, 4, 149-153.
202. Parman, T.; Wiley, M.J.; Wells, P.G. Free radical mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med., 1999, 5, 582-585.
203. Hansen, J.M.; Harris, C. A Novel hypothesis for Thalidomide-Induced Limb Teratogenesis: Redox Misregulation of the NF-kB Pathway. Antioxidants Redox Signaling, 2004, 6, 1-14.
204. Hansen, J.M.: Harris, K.K.; Philbert, M.A.; Harris, C. Thalidomide Modulates Nuclear Redox Status and Preferentially Depletes Glutathione in Rabbit Limb versus Rat Limb. JPET, 2002, 300, 768-776.
205. Knobloch, J.; Shaughnessy, J.D. Jr; Ruther, U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J., 2007, 21, 1410-1421.
206. Knobloch, J.; Schimitz, I.; Gotz, K.; Schulze-Osthoff, K.; Ruther, U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol., 2008, 28, 529-538.
207. Grotewold, L.; Ruther, U. The Wnt Antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. The EMBO Journal., 2002, 21, 966-975.
208. Ito, T.; Ando, H.; Handa, H. Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences, 2011, 68, 1569-1579.